Study of the molecular bases for the dynamics and dysfunction of dendritic cell subsets in tumor-bearing host

我们检测了具有向引流淋巴结迁移潜能的肿瘤浸润DC亚群，并鉴定了CCR7^+ MHC II类<hi>TIDCs作为具有抗原摄取和呈递潜能的淋巴结迁移DC的前体。趋化因子受体KO（CKO）小鼠和野生型与CKO混合骨髓嵌合体小鼠揭示了CCR2部分介导TIDCs的积累。我们还发现TIDCs在体内对抗癌药物具有相对抗性。基于这些结果，我们期望抗癌药物和CCR2靶向药物的联合治疗，增加TIDCs将提供一种新的抗癌免疫疗法。

We examined the tumor-infiltrating DC subsets with the potential to migrate to draining-lymph nodes and identified CCR7^+ MHC class II^<hi> TIDCs as the precursor of lymph node migratory DCs with antigen uptake and presentation potential. Chemokine receptor KO (CKO) mice and the wild type vs CKO mixed bone marrow chimera mice revealed that CCR2 partially mediates the accumulation of the TIDCs. We also found that the TIDCs were relatively resistant to the anti-cancer drug in vivo. Based on these results, we expect that the combination therapy of anti-cancer drug and CCR2 targeted drug that augment TIDCs would provide a novel anti-cancer immunotherapy.